Non-coding RNAs: New therapeutic targets and opportunities for hepatocellular carcinoma

Yu Cuiyun, Qian Ning, Zhi-Ping Li, Wen Huang, Jia Yu, Xiao-Yan Yang, Xiao-Yong Lei

Abstract


Non-coding RNAs (ncRNA) are RNA molecules without protein coding functions owing to the lack of an open reading frame (ORF). Based on the length, ncRNAs can be divided into long and short ncRNAs; short ncRNAs include miRNAs and piRNAs. Hepatocellular carcinoma (HCC) is among the most frequent forms of cancer worldwide and its incidence is increasing rapidly. Studies have found that ncRNAs are likely to play a crucial role in a variety of biological processes including the pathogenesis and progression of HCC. In this review, we summarized the regulation mechanism and biological functions of ncRNAs in HCC with respect to its application in HCC diagnosis, therapy and prognosis.

Keywords


hepatocellular carcinoma; ncRNA; miRNA; lncRNA; piRNA

Full Text:

PDF

References


Yu CY, Wang YM, Li NM, Liu GS, Yang S, Tang GT, He DX, Tan XW, Wei H. In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy. Mol Pharm 2014; 11(2): 638–644. doi: 10.1021/mp400412c.

Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin N Am 2010; 24(4): 899–919. doi: 10.1016/j.idc.2010.07.004.

Abdel-Rahman O. Hepatocellular carcinoma (HCC); aetiological considerations. Adv Mod Oncol Res 2015; 1(1): 18–19. doi: 10.18282/amor.v1.i1.8.

Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol 2015; 44(6): 479–486. doi: 10.1067/j.cpradiol.2015.04.004.

Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, Zhong Z, Valasek MA, Seki E, Hidalgo J, Koike K, Kaufman RJ, Karin M. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 2014; 26(3): 331–343. doi: 10.1016/j.ccr.2014.07.001.

Duan XY, Zhang L, Fan JG, Qiao L. NAFLD leads to liver cancer: Do we have sufficient evidence? Cancer Lett 2014; 345(2): 230–234. doi: 10.1016/j.canlet.2013.07.033.

Karagozian R, Derdák Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 2014; 63(5): 607–617. doi: 10.1016/j.metabol.2014.01.011.

Kessler SM, Simon Y, Gemperlein K, Gianmoena K, Cadenas C, Zimmer V, Pokorny J, Barghash A, Helms V, van Rooijen N, Bohle RM, Lammert F, Hengstler JG, Mueller R, Haybaeck J, Kiemer AK. Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma. Int J Mol Sci 2014; 15(4): 5762–5773. doi: 10.3390/ijms15045762.

He G, Karin M. NF-κB and STAT3 – key players in liver inflammation and cancer. Cell Res 2011; 21(1): 159–168. doi: 10.1038/cr.2010.183.

Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012; 56(2): 769–775. doi: 10.1002/hep.25670.

Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem S, Piiper A, Waidmann O. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 2013; 49(16): 3442–3449. doi: 10.1016/j.ejca.2013.06.002.

Utsunomiya T, Shimada M, Morine Y, Tajima A, Imoto I. Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis. Cancer Sci 2014; 105(7): 749–754. doi: 10.1111/cas.12431.

Scaggiante B, Kazemi M, Pozzato G, Dapas B, Farra R, Grassi M, Zanconati F, Grassi G. Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol 2014; 20(5): 1268–1288. doi: 10.3748/wjg.v20.i5.1268.

Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Xia JL, Wu ZQ, Fan J, Ma ZC, Zhou XD, Lin ZY, Liu KD. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin 2004; 130(4): 187–196. doi: 10.1007/s00432-003-0511-1.

Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009; 136(2): 215–233. doi: 10.1016/j.cell.2009.01.002.

Ghildiyal M, Zamore PD. Small silencing RNAs: An expanding universe. Nat Rev Genet 2009; 10: 94–108. doi: 10.1038/nrg2504.

Hou W, Bonkovsky HL. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: Dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol 2013; 19(44): 7836–7845. doi: 10.3748/wjg.v19.i44.7836.

Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet 2006; 15(s1): R17–R29. doi: 10.1093/hmg/ddl046.

Li G, Shen Q, Li C, Li D, Chen J, He M. Identification of circulating MicroRNAs as novel potential biomarkers for hepatocellular carcinoma detection: A systematic review and meta-analysis. Clin Transl Oncol 2015; 17(9): 684–693. doi: 10.1007/s12094-015-1294-y.

Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, Tian W, zhang Q, Wang C, Zhang Q, Zhuang SM, Zheng L, Liang A, Tao W, Cao X. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19(2): 232–243. doi: 10.1016/j.ccr.2011.01.001.

Song K, Han C, Zhang J, Lu D, Dash S, Feitelson M, Lim K, Wu T. Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology 2013; 58(5): 1681–1692. doi: 10.1002/hep.26514.

NakaoK, Miyaaki H, Ichikawa T. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol 2014; 49(4): 589–593. doi: 10.1007/s00535-014-0932-4.

Tsai WC, Hsu PWC, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD, Tsou AP. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009; 49(5): 1571–1582. doi: 10.1002/hep.22806.

Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovanni C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L, Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67(13): 6092–6099. doi: 10.1158/0008-5472.CAN-06-4607.

Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69: 5761–5767. doi: 10.1158/0008-5472.CAN-08-4797.

Xu H, He JH, Xiao ZD, Zhang QQ. Liver-enriched transcription factors regulate MicroRNA-122 that targets CUTL1 during liver development. Hepatology 2010; 52(4): 1431–1442. doi: 10.1002/hep.23818.

Xu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q, Wu F. MicroRNA-122 suppresses cell proliferation and induces cell apopto-sis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver Int 2012; 32(5): 752–760. doi: 10.1111/j.1478-3231.2011.02750.x.

Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y, Wang Q, Chen W, Zhuang SM. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 2010; 52(5): 1702–1712. doi: 10.1002/hep.23875.

Tsai WC, Hsu SD, Hsu CS, Lai TS, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M, Tsou AP. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122(8): 2884–2897. doi: 10.1172/JCI63455.

Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutry D, Croce CM, Bolondi L, Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010; 70(12): 5184–5193. doi: 10.1158/0008-5472.CAN-10-0145.

Song JG, Gao LC, Yang G, Tang S, Xie H, Wang Y, Wang J, Zhang Y, Jin J, Gou Y, Yang Z, Chen Z, Wu K, Liu J, Fan D. MiR-199a regulates cell proliferation and survival by targeting FZD7. PLoS One 2014; 9(10): e110074. doi: 10.1371/journal.pone.0110074.

Amr KS, Ezzat WM, Elhosary YA, Hegazy AE, Fahim HH, Kamel RR. The potential role of miRNAs 21 and 199-a in early diagnosis of hepatocellular carcinoma. Gene 2016; 575(1): 66–70. doi: 10.1016/j.gene.2015.08.038.

Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69(3): 1135–1142. doi: 10.1158/0008-5472.CAN-08-2886.

Xu L, Beckebaum S, Iacob S, Wu G, Kaiser GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, Lu M, Cicinnati VR. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol 2014; 60(3): 590–598. doi: 10.1016/j.jhep.2013.10.028.

Au SLK, Wong CCL, Lee JMF, Fan DNY, Tsang FH, Ng IOL, Wong CM. Enhancer of zeste homolog 2 epigenetically silences mul-tiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 2012; 56(2): 622–631. doi: 10.1002/hep.25679.

Sheng Y, Li J, Zou C, Wang S, Cao Y, Zhang J, Huang A, Tang H. Downregulation of miR-101-3p by hepatitis B virus promotes proliferation and migration of hepatocellular carcinoma cells by targeting Rab5a. Arch Virol 2014; 159(9): 2397–2410. doi: 10.1007/s00705-014-2084-5.

Wei X, Xiang T, Ren G, Tan C, Liu R, Xu X, Wu Z. miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal 2013; 25(2): 439–446. doi: 10.1016/j.cellsig.2012.10.013.

Liu YM, Xia Y, Dai W, Han HY, Dong YX, Cai J, Zeng X, Luo FY, Yang T, Li YZ, Chen J, Guan J. Cholesterol-conjugated let-7a mimics: antitumor efficacy on hepatocellular carcinoma in vitro and in a preclinical orthotopic xenograft model of systemic therapy. BMC Cancer2014; 14: 889. doi: 10.1186/1471-2407-14-889.

Cheng JC, Yeh YJ, Tseng CP, Hsu SD, Chang YL, Sakamoto N, Huang HD. Let-7b is a novel regulator of hepatitis C virus replication. Cell Mol Life Sci 2012; 69(15): 2621–2633. doi: 10.1007/s00018-012-0940-6.

Ge W, Yu DC, Li QG, Chen X, Zhang CY, Ding YT. Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances. Clin Lab 2014; 60(3): 427–434. doi: 10.7754/Clin.Lab.2013.130133.

Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhou W, Wang Z, Ding G, Zhuang SM, Zheng L, Tao W, Cao X. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 2011; 286(42): 36677–36685. doi: 10.1074/jbc.M111.270561.

Zhang J, Jin H, Liu H, Lv S, Wang B, Wang R, Liu H, Ding M, Yang Y, Li L, Zhang J, Fu S, Xie D, Wu M, Zhou W, Qian Q. MiRNA-99a directly regulates AGO2 through translational repression in hepatocellular carcinoma. Oncogenesis 2014; 3: e97. doi: 10.1038/oncsis.2014.11.

Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Bioph Res Co 2011; 406(1): 70–73. doi: 10.1016/j.bbrc.2011.01.111.

Wang Y, Toh HC, Chow P, Chung AYF, Meyers DJ, Cole PA, Ooi LLPJ, Lee CGL. MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J 2012; 26(7): 3032–3041. doi: 10.1096/fj.11-201855.

Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, Ghoshal K, Jacob ST. Methylation mediated silencing of microRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 2008; 68(13): 5049–5058. doi: 10.1158/0008-5472.CAN-07-6655.

Yang X, Yin J, Yu J, Xiang Q, Liu Y, Tang S, Liao D, Zhu B, Zu X, Tang H, Lei X. miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w. Oncol Rep 2012; 27(1): 250–257. doi: 10.3892/or.2011.1472.

Jiang C, Chen H, Shao L, Wang Q. MicroRNA-1 functions as a potential tumor suppressor in osteosarcoma by targeting Med1 and Med31. Oncol Rep 2014; 32(3): 1249–1256. doi: 10.3892/or.2014.3274.

Li D, Liu Y, Li H,Peng JJ, Tan Y, Zhou JJ, Xu T, Fu ZQ, Feng JQ, Cheng P, Chen T, Wei D, Su XM, Liu HY, Qi ZC, Tang LJ, Wang T, Guo X, Hu YH, Zhang T. MicroRNA-1 promotes apoptosis of hepatocarcinoma cells by targeting apoptosis inhibitor-5 (API-5). FEBS Lett 2015; 589(1): 68–76. doi: 10.1016/j.febslet.2014.11.025.

Li D, Yang P, Li H, Cheng P, Zhang L, Wei D, Su X, Peng J, Gao H, Tan Y, Zhao Z, Li Y, Qi Z, Rui Y, Zhang T. MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. Life Sci 2012; 91(11-12): 440–447. doi: 10.1016/j.lfs.2012.08.015.

Hu C, Shen SQ, Cui ZH, Chen ZB, Li W. Effect of microRNA-1 on hepatocellular carcinoma tumor endothelial cells. World J Gastroenterol 2015; 21(19): 5884–5892. doi: 10.3748/wjg.v21.i19.5884.

Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinogen 2013; 52(4): 297–303. doi: 10.1002/mc.21864.

Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovanni C, Croce CM, Bolondi L, Negrini M. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27(43): 5651–5661. doi: 10.1038/onc.2008.178.

Zhu Q, Wang Z, Hu Y, Li J, Li X, Zhou L, Huang Y. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep 2012; 27(5): 1660–1668. doi: 10.3892/or.2012.1682.

Xu G, Zhang Y, Wei J, Jia W, Ge Z, Zhang Z, Liu X. MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. BMC Cancer 2013; 13: 469. doi: 10.1186/1471-2407-13-469.

Qiu X, Dong S, Qiao F, Lu S, Song Y, Lao Y, Li Y, Zeng T, Hu J, Zhang L, Zhang L, Fan H. HBx-mediated miR-21 upregulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma. Oncogene 2013; 32(27): 3296–3305. doi: 10.1038/onc.2013.150.

Li Q, Ding C, Chen C, Zhang Z, Xiao H, Xie F, Lei L, Li J, Wang D, Wang G. miR-224 promotion of cell migration and invasion by targeting Homeobox D 10 gene in human hepatocellular carcinoma. J Gastroen Hepatol 2014; 29(4): 835–842. doi: 10.1111/jgh.12429.

Wang Yu, Ren J, Gao Y, Ma JZI, Toh HC, Chow P, Chung AYF, Ooi LLPJ, Lee CGL. MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival. PLoS ONE 2013; 8(7): e68744. doi: 10.1371/journal.pone.0068744.

Ma D, Tao X, Gao F, Fan C, Wu D. miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. Oncol Lett 2012; 4(3): 483–488. doi: 10.3892/ol.2012.742.

Lan SH, Wu SY Wu, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS. Autophagy-preferential degradation of MIR224 participates in hepatocellular carcinoma tumorigenesis. Autophagy 2014; 10(9): 1687–1689. doi: 10.4161/auto.29959.

Shi XF, Sun M, Liu HB, Yao Y, Song Y. Long non-coding RNAs: A new frontier in the study of human diseases. Cancer Lett 2013; 339(2): 159–166. doi: 10.1016/j.canlet.2013.06.013.

Li CH, Chen Y. Targeting long non-coding RNAs in cancers: Progress and prospects. Int J Biochem Cell B 2013; 45(8): 1895–1910. doi: 10.1016/j.biocel.2013.05.030.

He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, Li J. Long noncoding RNAs: Novel insights into hepatocelluar carcinoma. Cancer Lett 2014; 344(1): 20–27. doi: 10.1016/j.canlet.2013.10.021.

Panzitt K, Tschernatsch MMO, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatlouka K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007; 132(1): 330–342. doi: 10.1053/j.gastro.2006.08.026.

Peng W, Gao W, Feng J. Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol 2014; 31(12): 346. doi: 10.1007/s12032-014-0346-4.

Du Y, Kong G, You X, Zhang S, Zhang T, Gao Y, Ye L, Zhang X. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem 2012; 287(31): 26302–26311. doi: 10.1074/jbc.M112.342113.

Liu Y, Pan S, Liu L, Zhai X, Liu J, Wen J, Zhang Y, Chen J, Shen H, Hu Z. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. PLoS One 2012; 7(4): e35145. doi: 10.1371/ journal.pone.0035145.

Kim KS, Lee YI. Biallelic expression of the H19and IGF2 genes in hepatocellular carcinoma. Cancer Lett 1997; 119(2): 143–148. doi: 10.1016/S0304-3835(97)00264-4.

Lv J, Yu YQ, Li SQ, Luo L, Wang Q. Aflatoxin B1 promotes cell growth and invasion in hepatocellular carcinoma HepG2 cells through H19 and E2F1. Asian Pac J Cancer P 2014; 15(6): 2565–2570. doi: 10.7314/APJCP.2014.15.6.2565.

Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, Galun E. The H19 non-coding RNA is essential for human tumor growth. PLoS One 2007; 2(9): e845. doi: 10.1371/journal.pone.0000845.

Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene 2007; 26(33): 4877–4881. doi: 10.1038/sj.onc.1210266.

Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: A tumor suppressor. J Mol Endocrinol 2012; 48(3): R45–R53. doi: 10.1530/JME-12-0008.

Zhuo H, Tang J, Lin Z, Jiang R, Zhang X, Ji J, Wang P, Sun B. The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma. Mol Carcinog 2015; 55(2): 209–219. doi: 10.1002/mc.22270.

Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, Negrini M, Miotto E, Croce CM, Patel T. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011; 30(47): 4750–4756. doi: 10.1038/onc.2011.193.

Anwar SL, Krech T, Hasemeier B, Schipper E, Schweitzer N, Vogel A, Kreipe H, Lehmann U. Loss of Imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma. PLoS ONE.2012; 7(11): e49462. doi: 10.1371/journal.pone.0049462.

Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Müller-Tidow C. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22(39): 8031–8041. doi: 10.1038/sj.onc.1206928.

Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007; 26(6): 851–858. doi: 10.1038/sj.onc.1209846.

Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, Wu LM, Chen LM, Zheng SS. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 2012; 29(3): 1810–1816. doi: 10.1007/s12032-011-0004-z.

Ding C, Cheng S, Yang Z, Lv Z, Xiao H, Du C, Peng C, Xie H, Zhou L, Wu J, Zheng S. Long non-coding RNA HOTAIR promotes cell migration and invasion via down-regulation of RNA binding motif protein 38 in hepatocellular carcinoma cells. Int J Mol Sci 2014; 15(3): 4060–4076. doi: 10.3390/ijms15034060.

Geng YJ, Xie SL, Li Q, Ma J, Wang GY. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res 2011; 39(6): 2119–2128. doi: 10.1177/147323001103900608.

Yang Z, Zhou L, Wu LM, Lai MC, Xie HY, Zhang F, Zheng SS. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011; 18(5): 1243–1250. doi: 10.1245/s10434-011-1581-y.

Kim VN. Small RNAs just got bigger: Piwi-interacting RNAs (piRNAs) in mammalian testes. Gene Dev 2006; 20(15): 1993–1997. doi: 10.1101/gad.1456106.

Aravin A, Gaidatzis D, Pfeffer S, Lagos-Quintana M, Landgraf P, Iovino N, Morris P, Brownstein MJ, Kuramochi-Miyagawa S, Nakano T, Chien M, Russo JJ, Ju J, Sheridan R, Sander C, Zavolan M, Tuschl T. A novel class of small RNAs bind to MILI protein in mouse testes. Nature 2006; 442(7099): 203–207. doi: 10.1038/nature04916.

Mei Y, Clark D, Mao L. Novel dimensions of piRNAs in cancer. Cancer Lett2013; 336(1): 46–52. doi: 10.1016/j.canlet.2013.04.008.

Girard A, Sachidanandam R, Hannon GJ, Carmell MA. A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature 2006; 442(7099): 199–202. doi: 10.1038/nature04917.

Zheng J, Dong P, Gao S, Wang N, Yu F. High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma. Hepatogastroenterology 2013; 60(123): 549–552. doi: 10.5754/hge12754.

Tan Y, Lin B, Ye Y, Wen D, Zhou X. Differential expression of serum microRNAs in cirrhosis that evolve into hepatocellular carcinoma related to hepatitis B virus. Oncol Rep 2015; 33(6): 2863–2870. doi: 10.3892/or.2015.3924.

Hung CH, Hu TH, Lu SN, Kuo FY, Chen CH, Wang JH, Huang CM, Lee CM, Lin CY, Yen YH, Chiu YC. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. Int J Cancer 2015; 138(3): 714–720. doi: 10.1002/ijc.29802.

El-Garem H, Ammer A, Shehab H, Shaker O, Anwer M, El-Akel W, Omar H. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol 2014; 6(11): 818–824. doi: 10.4254/wjh.v6.i11.818.

Lou W, Chen Q, Ma L, Liu J, Yang Z, Shen J, Cui Y, Bian XW, Qian C. Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superiorantitumor activity in experimental tumor model. J Mol Med 2013; 91(6): 715–725. doi: 10.1007/s00109-012-0985-x.

Yu CY, Li NM, Yang S, Ning Q, Huang C, Huang W, He ZN, He DX, Tan XW, Sun LC. Fabrication of galactosylated chitosan-5-fluorouracil acetic acid based nanoparticles for controlled drug delivery. J Appl Polym Sci 2015; 132(40): 42625. doi: 10.1002/app.42625.

Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010; 103(10): 1617–1626. doi: 10.1038/sj.bjc.660595.

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IOL, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361(15): 1437–1447. doi: 10.1056/NEJMoa0901282.

Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int 2013; 2013(2013): 136106. doi: 10.1155/2013/136106.

Tang J, Zhuo H, Zhang X, Jiang R, Ji J, Deng L, Qian X, Zhang F, Sun B. A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma. Cell Death Dis 2014; 5: e1549. doi: 10.1038/cddis.2014.518.

Yang X, Xie X, Xiao YF, Xie R, Hu CJ, Tang B, Li BS, Tang SM. The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma. Cancer Lett 2015; 360(2): 119–124. doi: 10.1016/j.canlet.2015.02.035.

Wu J, Qin Y, Li B, He WZ, Sun ZL. Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma. Genomics 2008; 91(5): 443–450. doi: 10.1016/j.ygeno.2008.01.007.

Ishibashi M, Kogo R, Shibata K, Sawada G, Takahashi Y, Kurashige J, Akiyoshi S, Sasaki S, Iwaya T, Sudo T, Sugimachi K, Mimori K, Wakabayashi G, Mori M. Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. Oncol Rep 2013; 29(3): 946–950. doi: 10.3892/or.2012.2219.

Wu J, Xie H. Expression of long noncoding RNA-HOX transcript antisense intergenic RNA in oral squamous cell carcinoma and effect on cell growth. Tumour Biol 2015; 36(11): 8573–8578. doi: 10.1007/s13277-015-3598-5.

Yang H, Zhong Y, Xie H, Lai X, Xu M, Nie Y, Liu s, Wan YJY. Induction of the liver cancer-down-regulated long noncoding RNA uc002mbe.2 mediates trichostatin-induced apoptosis of liver cancer cells. Biochem Pharmacol 2013; 85(12): 1761–1769. doi: 10.1016/j.bcp.2013.04.020.

Yuan SX, Yang F, Yang Y, Tao QF, Zhang J, Huang G, Yang Y, Wang RY, Yang S, Huo XS, Zhang L, Wang F, Sun SH, Zhou WP. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients’ poor recurrence-free survival after hepatectomy. Hepatology 2012; 56(6): 2231–2241. doi: 10.1002/hep.25895.

Huang JL, Zheng L, Hu YW, Wang Q. Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis 2014; 35(3): 507–514. doi: 10.1093/carcin/bgt405.




DOI: http://dx.doi.org/10.30564/amor.v2i1.27

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Yu Cuiyun, Qian Ning, Zhi-Ping Li, Wen Huang, Jia Yu, Xiao-Yan Yang, Xiao-Yong Lei

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.